Paper Title
Study of High Sensitive C-Reactiveprotein (Hscrp)As Prognostic Marker in Pulmonary Tuberculosis Patients

Abstract
Tuberculosisis an infectious disease caused by Mycobacterium tuberculosis. It is the major public health problem and ninth leading cause of death worldwide. TB is highest burden in India. Mycobacterium tuberculosisusually affects the lung and causes pulmonary tuberculosis but other organs are involved in up to one third of cases. hsCRPis an acute phase protein and inflammatory markers for both acute and chronic inflammation. hsCRP is a sensitive indicator of inflammation in pulmonary tuberculosis and proper evaluation of hsCRP in pre and post treatment indicates therapeutic response. Aim- To estimate serum level of hsCRP in pre and post treatment of newly diagnosed pulmonary tuberculosis patients. Material & methods:- The present study was conducted in Department of Biochemistry, Department of Pulmonary Medicine, SGT Medical College, Hospital & Research Institute, SGT University, Budhera, Gurugram and District TB Centre, Gurugram, Haryana, India. The 100 newly diagnosed pulmonary tuberculosis patients were included of age group more than 15 years from OPD, IPD and DOTS centre of SGT Medical College, Hospital & Research Institute, SGT University, Budhera, Gurugram and District TB Centre, Gurugram. The venous blood sample was collected as per guidelines of RNTCP (DOTS) in pre and post treatment. The level of serum hsCRPwas analyzed by ELISA method (Calbiotech ELISA KIT). Result:- The increased level of serum hsCRP in pre-treatment (8.69±4.85 mg/L) compared to post treatment (3.86±2.04 mg/L) with p<0.01. Conclusion:- The level of serum hsCRP was decreased in post-treatment in comparison of pre-treatment in pulmonary tuberculosis patients. Thus, it signifies the effect of anti-tubercular treatment and play role as prognostic marker in pulmonary tuberculosis patients. Key words:- High sensitive C-reactive protein (hsCRP), Tuberculosis(TB), Pulmonary tuberculosis (PTB), Anti-tubercular treatment (ATT), Directly observed treatment short course (DOTS).